For a clinician noticing an adverse drug effect during their management of pharmacotherapy, the act of filling in an ADR report represents an important opportunity for learning.
INTERACTIVE TECHNIQUES FOR
LEARNING PHARMACOVIGILANCE
For
a clinician noticing an adverse drug effect during their management of
pharmacotherapy, the act of filling in an ADR report represents an important
opportunity for learning. Too frequently, this opportunity for learning is
lost.
Regrettably
in most settings, insufficient resources are available to allow routine
interaction between the reporting clinician and staff of the national/regional
authority who record and codify such reports. Certainly for those reported
events where there is a suspicion that a significant new signal may be
involved, such feedback and interaction has become more prevalent in recent
years. However for events that appear superficially to be more mundane,
effec-tive educational interaction with monitoring authori-ties rarely occurs.
There
may be many ways to remedy this lost opportunity, and certainly in some local
institutional settings, discussion of, and interaction about ADR reports
becomes a matter of routine. Such arrangements need to be purposefully
fostered. Multi-disciplinary hospital drug and therapeutics advisory committees
can be a useful forum for such learning, and in settings where high-level
clinical pharmacy practice is in place, the clinical pharmacy practitioner can
be an empowering influence to catalyse discussion about, and learning from any
jointly observed incident.
Encouragement
of more formal interactive local learning circles represents a further
important oppor-tunity to be fostered: such circles have taken many forms in
Europe with 10 countries being judged to have ‘substantial activities’ in this
format. In partic-ular, such multidisciplinary groups have been in place
amongst community-based practitioners in the Netherlands for more than 25 years
and have proven themselves to be effective in gaining changes in history
taking, communication with patients, follow-up decisions and drug prescribing
(van Eijk et al., 2001; Beyer et al., 2003).
Higher
levels of ongoing educational attainment are now being required for the
maintenance of professional practice accreditation by many profes-sional
authorities associated with medical and allied health disciplines. These
developments provide an opportunity for more disciplined approaches to
phar-macovigilance learning and education at the clini-cal practitioner level.
In particular, interactive audit and feedback requirements within continuing
medical education programmes are becoming more prevalent, and this form of
Continuing Medical Education offers many opportunities for personal exploration
of unex-pected drug-related events in relation to established pharmacovigilance
knowledge.
After
many years as a concept being subjected solely to research, a considerable
number of countries have now begun developing interactive, one-on-one public
interest–oriented academic detailing programmes for primary care practitioners.
Such programmes have largely been oriented to providing commercially unbiased
information concerning therapeutic and diagnostic issues. Social marketing, or
the ‘sell-ing’ of patient outcome–improving ideas/evidence according to
perceived needs of individual prac-titioners, is central to this academic
detailing concept.
Ongoing
initiatives of this kind aimed at public health improvement have been
established in a vari-ety of countries including the United Kingdom, Belgium,
Canada and Australia. Generally speaking, these programmes have fostered
supportive relation-ships with primary care practitioners, which have then
spear-headed application of additional educational and behaviour-changing
initiatives.
In
Australia, a National Prescribing Service has been extending academic
detailing–led programmes throughout the Australian continent. These programmes
have aimed for the improvement of general practitioner (GP) discrimination in
their use of pharmacotherapies as well as for overall better health outcomes
(NPS, 2005). The GP– academic–detailer relationships have then been used to
increase credibility and uptake of a range of other NPS-initiated practice
improvement programmes.
The
central approach taken in these service-oriented programmes has often been to
deliver key clinical behaviour-change messages targeting achievement of the
most judicious balance of benefit and risk associ-ated with pharmacotherapies
(May and Rowett, 2000). In this context, these public interest programmes
provide an effective vehicle for the delivery of phar-macovigilance learning
into primary care practice: steps need to be taken to integrate findings from
pharmacovigilance studies into the activities of such groups.
One
of the features of one-to-one social marketing– driven encounters is the
opportunity for the place-ment of constantly evolving evidence about risks and
benefits of pharmaceuticals into a context of uncertainty. This context of
scientific uncertainty then joins seamlessly with the professional’s daily
expe-rience of uncertainty in their own clinical practice (McWhinney, 1997).
Another of the central tenets of the academic detailing model is the
acknowledgement of both sides of controversial issues (Soumerai and Avorn,
1990).
This
interactive presentation of pharmacovigilance messages stands in contrast with
conventional use of the printed word for such communications: static delivery
of this information in letters or label warn-ings frequently needs
qualification for it to be entirely true and fair.
Academic
detailing–spearheaded initiatives are ideal carriers for pharmacovigilance
messages, plac-ing complex information into a context that reliably modulates
individual clinical practice.
The
use of reminders was also characterized by Bloom as an additional effective
interactive tech-nique for achieving clinical practice professional behaviour
change. The steady increase in the adoption of electronic systems of record
keeping in health-care practice (including primary care) has created the
opportunity for broader use of electronic reminders in computer-based
prescription management software. These systems have been found to be generally
effec-tive in issues such as drug dosage selection and also for providing
general triggers for prudent monitor-ing of ongoing pharmacotherapies (Hunt et al., 1998). An increasingly broad
understanding is being gained of barriers to the use of such systems in routine
clini-cal care: further improvement of their dovetailing into operational
patterns of clinical care will increase their usefulness over time.
The
potential for the integration of electronic cautionary notes into such systems
offers a further opportunity for translating pharmacovigilance-derived
knowledge into practice. The critical nature of the functional design and
operational ease-of-use of such software-based reminder systems remains a key
chal-lenge for their developers (Patterson et
al., 2005). Such reminder systems are most practical for phar-macovigilance
messages where only few uncertainties exist about the nature of the response
called for by practitioners: unfortunately, such circumstances are relatively
unusual. The deterministic nature of much currently available software limits
its usefulness for educationally effective delivery of electronic reminder
warnings.
Related Topics
TH 2019 - 2025 pharmacy180.com; Developed by Therithal info.